Document Detail

Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: A nationwide population-based cohort study.
MedLine Citation:
PMID:  23218193     Owner:  NLM     Status:  Publisher    
BACKGROUND: Statin has potential protective effects against atrial fibrillation. Clinically, there is a need to predict the atrial fibrillation protective effects in statin-treated patients. The purpose of this study was to investigate if cardiovascular co-morbidities or cumulative defined daily doses (cDDDs) of statin use could predict statin efficacy in atrial fibrillation prevention. METHODS: Patients aged ≥50years were identified from the Taiwan National Health Insurance Research Database. Medical records of 171,885 patients were used in this study, and 40,001 (23.3%) of the patients received statin therapy (≥28 cDDDs). Risk of new-onset atrial fibrillation in statin users and non-users (<28 cDDDs) was estimated. RESULTS: During the 9-year follow-up period, 6049 patients experienced new-onset atrial fibrillation. Overall, statin therapy reduced the risk of atrial fibrillation by 28% (adjusted hazard ratio [HR] 0.72; 95% CI 0.68 to 0.77). There was a dose-response relationship between statin use and the risk of atrial fibrillation. The adjusted HRs for atrial fibrillation were 1.04, 0.85, and 0.50 when cDDDs ranged from 28 to 90, 91 to 365, and more than 365, respectively. Subgroup analysis showed that statin use was more beneficial in patients with higher CHADS(2) and CHA(2)DS(2)VASc scores than those with a score of 0 (P value for interaction<0.001). The therapy provided no obvious beneficial effect in those with a CHADS(2) score of 0, a CHA(2)DS(2)VASc score of 0, or cDDDs less than 91. CONCLUSIONS: Statin therapy reduces the risk of new-onset atrial fibrillation in a dose-dependent manner, and is beneficial in patients with cardiovascular co-morbidities.
Chen-Ying Hung; Ching-Heng Lin; Kuo-Yang Wang; Jin-Long Huang; Yu-Cheng Hsieh; El-Wui Loh; Tsuo-Hung Lan; Pesus Chou; Chih-Tai Ting; Tsu-Juey Wu
Related Documents :
22061043 - Patient-specific measures of a biomarker for the generation of individual reference int...
24617913 - Vernakalant hydrochloride to treat atrial fibrillation.
16183413 - Delay in time to receipt of thrombolytic medication among medicare patients with kidney...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-2
Journal Detail:
Title:  International journal of cardiology     Volume:  -     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multidimensional gas chromatography for the characterization of permanent gases and light hydrocarbo...
Next Document:  Pulmonary Vein Thrombosis Associated with a Large Hiatal Hernia.